NYSE$LH
Laboratory Corp Of America Holdings · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Announced fourth quarter and full-year results, providing 2023 guidance.
Labcorp's Q4 2022 results showed a revenue of $3.7 billion, a decrease from $4.1 billion in the previous year, with diluted EPS at $0.86 compared to $5.75. The company experienced a decrease in COVID-19 testing revenue but saw growth in its base business. They also provided full-year 2023 guidance, including adjusted EPS of $16.00 to $18.00 and free cash flow of $1.0 billion to $1.2 billion.
- Revenue for Q4 was $3.7 billion, compared to $4.1 billion last year.
- Diluted EPS for Q4 was $0.86, versus $5.75 last year.
- Adjusted EPS for Q4 was $4.14, compared to $6.77 last year.
- Free Cash Flow for Q4 was $536 million, versus $548 million last year.
Headline financials
Revenue & EPS history
LabCorp · Revenue · Quarterly
$3.67B
Revenue by segment
LabCorp · $3.68B total across 2 segments · Q4 2022
- Diagnostics Laboratories$2.29B-12.7%62.2%
- Biopharma Laboratory Services$1.39B-4.3%37.8%
Forward guidance
Labcorp provided full-year 2023 guidance, including adjusted EPS of $16.00 to $18.00 and free cash flow of $1.0 billion to $1.2 billion.
Tailwinds
- Base Business revenue growth in Diagnostics is expected to be between 10.5% and 12.5%.
- Total Drug Development revenue is expected to grow between 5.0% and 7.0%.
- The company anticipates a positive impact from capital allocation, including acquisitions, share repurchases, and dividends.
- The guidance assumes that the Clinical Development business will be with Labcorp for the full year.
- Free Cash Flow is expected to be between $1.0 billion and $1.2 billion.
Headwinds
- COVID-19 Testing revenue is expected to decline by 90.0% to 75.0%.
- Total Diagnostics revenue is expected to decline between 2.0% and grow 1.5%.
- 2023 Guidance includes an impact from foreign currency translation of 0.0%.
- 2023 Guidance includes an impact from foreign currency translation of (0.2%) for total diagnostics.
- 2023 Guidance includes an impact from foreign currency translation of 0.2% for total drug development.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
-0.3%
Avg return
Earnings day
-0.6%
Avg return
5 days after
-0.9%
Avg return
30 days after
48%
35 / 73 earnings
Positive
+9.5%
Q2 2024
Best reaction
-10.4%
Q3 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.0% | +0.0% | +1.3% | |
| Q4 2025 | -2.1% | +0.0% | -6.6% | |
| Q3 2025 | -5.7% | -7.9% | -2.7% | |
| Q2 2025 | -0.5% | +1.2% | +2.0% | |
| Q1 2025 | +4.7% | +7.9% | +7.5% | |
| Q4 2024 | -0.9% | -1.9% | +1.2% | |
| Q3 2024 | +4.0% | +3.7% | +9.0% | |
| Q2 2024 | +9.5% | +4.8% | +6.7% | |
| Q1 2024 | -4.6% | -3.2% | -4.0% | |
| Q4 2023 | -5.0% | -5.5% | -8.3% | |
| Q3 2023 | +0.6% | +1.0% | +7.6% | |
| Q2 2023 | -1.9% | -2.4% | -3.0% | |
| Q1 2023 | -4.6% | -2.5% | -8.2% | |
| Q4 2022 | +3.2% | -0.4% | -14.1% | |
| Q3 2022 | -2.5% | -3.2% | +5.0% | |
| Q2 2022 | +5.1% | +1.2% | -8.1% | |
| Q1 2022 | -5.0% | -3.1% | +1.9% | |
| Q4 2021 | -1.9% | -6.0% | -5.7% | |
| Q3 2021 | +2.3% | +2.0% | +3.1% | |
| Q2 2021 | +4.6% | +6.0% | +6.1% | |
| Q1 2021 | +1.2% | +4.1% | +4.5% | |
| Q4 2020 | +4.0% | +3.1% | +4.1% | |
| Q3 2020 | +1.0% | -1.1% | -2.7% | |
| Q2 2020 | -3.3% | -4.2% | -13.4% | |
| Q1 2020 | -6.5% | -10.4% | -0.4% | |
| Q4 2019 | +4.1% | +1.8% | -19.5% | |
| Q3 2019 | -2.0% | -2.3% | +0.4% | |
| Q2 2019 | -6.5% | -4.2% | -6.9% | |
| Q1 2019 | +3.7% | +6.1% | +5.1% | |
| Q4 2018 | +2.5% | +3.8% | +3.7% | |
| Q3 2018 | -7.1% | -6.2% | -4.1% | |
| Q2 2018 | -5.4% | -6.4% | -5.3% | |
| Q1 2018 | +3.9% | +2.8% | +9.7% | |
| Q4 2017 | +3.9% | +3.0% | +5.9% | |
| Q3 2017 | +1.7% | +2.2% | +0.2% | |
| Q2 2017 | +2.0% | +1.3% | -1.4% | |
| Q1 2017 | -4.1% | -3.1% | -1.9% | |
| Q4 2016 | +2.4% | +2.4% | +5.4% | |
| Q3 2016 | -10.4% | -9.4% | -7.9% | |
| Q2 2016 | +0.4% | +1.2% | -1.4% | |
| Q1 2016 | +4.1% | — | — | |
| Q4 2015 | +2.8% | — | — | |
| Q3 2015 | +7.8% | — | — | |
| Q2 2015 | +3.8% | — | — | |
| Q1 2015 | -2.7% | — | — | |
| Q4 2014 | +4.9% | — | — | |
| Q3 2014 | +3.5% | — | — | |
| Q2 2014 | -0.5% | — | — | |
| Q1 2014 | -0.7% | — | — | |
| Q4 2013 | +1.1% | — | — | |
| Q3 2013 | -3.2% | — | — | |
| Q2 2013 | +0.0% | — | — | |
| Q1 2013 | +0.7% | — | — | |
| Q4 2012 | -1.7% | — | — | |
| Q3 2012 | -4.0% | — | — | |
| Q2 2012 | -9.0% | — | — | |
| Q1 2012 | -3.4% | — | — | |
| Q4 2011 | +2.2% | — | — | |
| Q3 2011 | -6.6% | — | — | |
| Q2 2011 | -0.6% | — | — | |
| Q1 2011 | +1.4% | — | — | |
| Q4 2010 | -0.2% | — | — | |
| Q4 2007 | -0.2% | — | — | |
| Q3 2010 | +1.6% | — | — | |
| Q2 2010 | +0.9% | — | — | |
| Q1 2009 | +1.8% | — | — | |
| Q1 2010 | +1.6% | — | — | |
| Q4 2009 | -0.4% | — | — | |
| Q2 2008 | -1.6% | — | — | |
| Q3 2009 | -1.6% | — | — | |
| Q3 2008 | -1.6% | — | — | |
| Q4 2008 | -1.4% | — | — | |
| Q2 2009 | -1.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro